Basic Information
| LncRNA/CircRNA Name | PCAT7 |
| Synonyms | PCAT7, PCAN-R2 |
| Region | GRCh38_9:94555054-94603990 |
| Ensemble | ENSG00000231806 |
| Refseq | NR_121566 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Paclitaxel | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | NSCLC tissues, cell lines (SUNE-1, CNE-1, HNE-1, CNE-2, C666-1 and HONE-1) |
| Expression Pattern | up-regulated |
| Function Description | Overexpression of PCAT7 resulted in the promotion of tumor cell proliferation,inhibition of cells apoptosis, facilitation of cells metastasis, and formation of EMT phenotype, while PCAT7 expression deletion remarkably prohibited cell proliferation, accelerated their apoptosis, weakened metastasis, and reversed EMT to MET.PCAT7 participates in tumor progression in NSCLC by inhibiting miR-134-5p.higher PCAT7 expression implied a worse survival rate in NPC patients. |
| Pubmed ID | 29275424 |
| Year | 2017 |
| Title | Long Non-Coding RNA Prostate Cancer-Associated Transcript 7 (PCAT7) Induces Poor Prognosis and Promotes Tumorigenesis by Inhibiting mir-134-5p in Non-Small-Cell Lung (NSCLC). |
External Links
| Links for PCAT7 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |